(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 4.77% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Zoetis's revenue in 2025 is $9,286,000,000.On average, 7 Wall Street analysts forecast ZTS's revenue for 2025 to be $4,226,397,444,605, with the lowest ZTS revenue forecast at $4,196,976,315,631, and the highest ZTS revenue forecast at $4,243,723,161,196. On average, 7 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,497,096,406,655, with the lowest ZTS revenue forecast at $4,439,169,496,463, and the highest ZTS revenue forecast at $4,542,057,077,511.
In 2027, ZTS is forecast to generate $4,750,927,771,200 in revenue, with the lowest revenue forecast at $4,643,702,528,092 and the highest revenue forecast at $4,893,616,952,187.